CLEVELAND--()--Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its panel of inflammation biomarkers will be featured at next week’s TEDMED 2012 conference in Washington. The annual conference, being held April 10-13, explores the issues, challenges and innovations that are shaping the future of health and medicine.
“We are thrilled to be participating in TEDMED 2012 and highlighting our advanced approach to assessing cardiovascular disease risk”
Conference participants may choose to receive inflammation testing that uses CHL’s proprietary biomarkers and the company’s advanced approach to inflammation. The degree of inflammation in one’s arteries is a better predictor of heart attack and stroke than cholesterol or other testing alone.
“We are thrilled to be participating in TEDMED 2012 and highlighting our advanced approach to assessing cardiovascular disease risk,” said Jake Orville, president and chief executive of CHL. “Our test panels offer broader prognostic coverage than traditional blood tests, enabling a determination of the degree to which someone is at risk for cardiovascular disease. TEDMED 2012, with its focus on health care innovation that drives systemic improvement, is an outstanding platform from which to highlight our approach and we are grateful for the opportunity.”
The company also said it will launch a new campaign focused on inflammation testing next week. The campaign will seek to raise awareness of inflammation testing and its importance with physicians, nurses and other health care professionals, and patients.
About Cleveland HeartLab
Cleveland HeartLab Inc. is a specialty clinical laboratory and cardiovascular disease management company focused on offering a robust menu of propriety diagnostic tests based on unique molecular biomarkers. CHL operates a CLIA-certified and CAP-accredited clinical laboratory. It has developed a panel of tests that thousands of practitioners use in the management and prevention of heart disease. CHL also runs a research and development laboratory where next-generation cardiovascular disease biomarkers are being developed for use through CHL’s clinical laboratory. This valuable pipeline of tests is part of an exclusive intellectual property portfolio that targets large, under-addressed markets. For more information about Cleveland HeartLab, please visit the company’s website at www.clevelandheartlab.com.